139 Entire-vial dosing of emicizumab 14. Schrijvers LH, Cnossen MH, Beijlevelt-Van der Zande M, Peters M, Schuurmans MJ, Fischer K. Defining adherence to prophylaxis in haemophilia. Haemophilia. 2016; 22: e311-314. 15. Wang SS, Yan YS, Ho K. US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives. Antib Ther. 2021; 4: 262-272. 16. Retout S, Schmitt C, Petry C, Mercier F, Frey N. Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A. Clin Pharmacokinet. 2020; 59: 1611-1625. 17. Schmitt C, Emrich T, Chebon S, Fernandez E, Petry C, Yoneyama K, Kiialainen A, Howard M, Niggli M, Paz-Priel I, Chang T. Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia. 2021; 27: 984-992. 18. Castaman G, Santoro C, Coppola A, Mancuso ME, Santoro RC, Bernardini S, Pugliese FR, Lubrano R, Golato M, Tripodi A, Rocino A, Santagostino E, ad hoc Working G, Biasoli C, Borchiellini A, Catalano A, Contino L, Coluccia A, Cultrera D, De Cristofaro R, Di Minno G, Fabbri A, Franchini M, Gamba G, Giuffrida AC, Gresele P, Giampaolo A, Hassan HJ, Luciani M, Marchesini E, Marino R, Mazzucconi MG, Molinari AC, Morfini M, Notarangelo LD, Peccarisi L, Peyvandi F, Pollio B, Rivolta GF, Ruggieri MP, Sargentini V, Schiavoni M, Sciacovelli L, Serino ML, Siragusa S, Tagliaferri A, Testa S, Tosetto A, Zampogna S, Zanon E. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus. 2020; 18: 143-151. 19. Sun SX, Frick A, Balasa V, Roberts JC. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A. Expert Rev Hematol. 2022: 1-8. 20. Bach PB, Conti RM, Muller RJ, Schnorr GC, Saltz LB. Overspending driven by oversized single dose vials of cancer drugs. BMJ. 2016; 352: i788. 21. Mahajerin A, Faghmous I, Kuebler P, Howard M, Xu T, Flores C, Chang T, Nissen F. Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A. J Comp Eff Res. 2022; 11: 717-728. 22. Foubert A, Roussel N, Chantrain VA, Hermans C, Lambert C, Lobet S, Meeus M. Pain coping behaviour strategies in people with haemophilia: A systematic literature review. Haemophilia. 2022 2022; 28: 902-916. 7
RkJQdWJsaXNoZXIy MTk4NDMw